Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Y8F

Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30o and GRIP Peptide

7Y8F の概要
エントリーDOI10.2210/pdb7y8f/pdb
分子名称Estrogen receptor, Grip peptide, DI(HYDROXYETHYL)ETHER, ... (6 entities in total)
機能のキーワードcomplex, inhibitor, estrogen receptor alpha, transcription-inhibitor complex, transcription/inhibitor
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数4
化学式量合計60850.31
構造登録者
Min, J.,Hu, H.B.,Yang, Y.,Dong, C.E.,Zhou, H.B.,Chen, C.-C.,Guo, R.-T. (登録日: 2022-06-23, 公開日: 2023-04-26, 最終更新日: 2023-11-29)
主引用文献Xin, L.,Min, J.,Hu, H.,Li, Y.,Du, C.,Xie, B.,Cheng, Y.,Deng, X.,Deng, X.,Shen, K.,Huang, J.,Chen, C.C.,Guo, R.T.,Dong, C.,Zhou, H.B.
Structure-guided identification of novel dual-targeting estrogen receptor alpha degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Eur.J.Med.Chem., 253:115328-115328, 2023
Cited by
PubMed Abstract: Drug resistance is a major challenge in conventional endocrine therapy for estrogen receptor (ER) positive breast cancer (BC). BC is a multifactorial disease, in which simultaneous aromatase (ARO) inhibition and ERα degradation may effectively inhibit the signal transduction of both proteins, thus potentially overcoming drug resistance caused by overexpression or mutation of target proteins. In this study, guided by the X-ray structure of a hit compound 30a in complex with ER-Y537S, a structure-based optimization was performed to get a series of multiacting inhibitors targeting both ERα and ARO, and finally a novel class of potent selective estrogen receptor degraders (SERDs) based on a three-dimensional oxabicycloheptene sulfonamide (OBHSA) scaffold equipped with aromatase inhibitor (AI) activity were identified. Of these dual-targeting SERD-AI hybrids, compound 31q incorporating a 1H-1,2,4-triazole moiety showed excellent ERα degradation activity, ARO inhibitory activity and remarkable antiproliferative activity against BC resistant cells. Furthermore, 31q manifested efficient tumor suppression in MCF-7 tumor xenograft models. Taken together, our study reported for the first time the highly efficient dual-targeting SERD-AI hybrid compounds, which may lay the foundation of translational research for improved treatment of endocrine-resistant BC.
PubMed: 37037140
DOI: 10.1016/j.ejmech.2023.115328
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.22 Å)
構造検証レポート
Validation report summary of 7y8f
検証レポート(詳細版)ダウンロードをダウンロード

227561

件を2024-11-20に公開中

PDB statisticsPDBj update infoContact PDBjnumon